IL236996A0 - Pharmaceutical preparations containing quaternized piperidinium salts - Google Patents
Pharmaceutical preparations containing quaternized piperidinium saltsInfo
- Publication number
- IL236996A0 IL236996A0 IL236996A IL23699615A IL236996A0 IL 236996 A0 IL236996 A0 IL 236996A0 IL 236996 A IL236996 A IL 236996A IL 23699615 A IL23699615 A IL 23699615A IL 236996 A0 IL236996 A0 IL 236996A0
- Authority
- IL
- Israel
- Prior art keywords
- piperidinium
- pharmaceutical compositions
- quaternary salts
- quaternary
- salts
- Prior art date
Links
- NQRYJNQNLNOLGT-UHFFFAOYSA-O Piperidinium(1+) Chemical compound C1CC[NH2+]CC1 NQRYJNQNLNOLGT-UHFFFAOYSA-O 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000003839 salts Chemical group 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/54—Sulfur atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261681415P | 2012-08-09 | 2012-08-09 | |
| PCT/US2013/052626 WO2014025569A1 (en) | 2012-08-09 | 2013-07-30 | Piperidinium quaternary salts |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL236996A0 true IL236996A0 (en) | 2015-03-31 |
Family
ID=50068488
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL236996A IL236996A0 (en) | 2012-08-09 | 2015-01-29 | Pharmaceutical preparations containing quaternized piperidinium salts |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US9896416B2 (enExample) |
| EP (1) | EP2882711B1 (enExample) |
| JP (1) | JP6345665B2 (enExample) |
| KR (2) | KR102240999B1 (enExample) |
| CN (2) | CN104603108A (enExample) |
| AU (1) | AU2013300009B2 (enExample) |
| BR (1) | BR112015002832B1 (enExample) |
| CA (1) | CA2881182C (enExample) |
| EA (1) | EA029678B9 (enExample) |
| HK (1) | HK1211572A1 (enExample) |
| IL (1) | IL236996A0 (enExample) |
| IN (1) | IN2015DN01018A (enExample) |
| MX (1) | MX356386B (enExample) |
| WO (1) | WO2014025569A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2978201A1 (en) | 2015-03-06 | 2016-09-15 | Chase Pharmaceuticals Corporation | Use of oxybutynin transdermal formulations to reduce side effects associated with muscarinic agonists |
| WO2017015349A1 (en) * | 2015-07-20 | 2017-01-26 | Chase Pharmaceuticals Corporation | Muscarinic combination of a selective m2-antagonist and a peripheral non-selective antagonist for treating hypocholinergic disorders |
| JP7365613B2 (ja) | 2019-08-22 | 2023-10-20 | オフィノ， エルエルシー | マルチアクセスに対するポリシー制御 |
| CN117018194A (zh) * | 2023-07-26 | 2023-11-10 | 同济大学 | 毒蕈碱型受体5型受体拮抗剂的用途 |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DD106643A1 (enExample) | 1973-07-12 | 1974-06-20 | ||
| CN1285348A (zh) | 1999-08-20 | 2001-02-28 | 广东康美药业股份有限公司 | 盐酸丙哌维林合成工艺 |
| DE10129832A1 (de) | 2001-06-17 | 2003-07-10 | Berolina Drug Dev Ab Svedala | Deuterierte N- und alpha-substituierte Diphenylalkoxyessigsäureaminoalkylester sowie diese Verbindungen enthaltende Arzneimittel |
| CA2384922C (en) * | 2002-05-03 | 2008-09-02 | Purepharm Inc. | Topical glycopyrrolate product for the reduction of sweating |
| KR100500760B1 (ko) | 2003-07-22 | 2005-07-14 | 동방에프티엘 주식회사 | 염산 프로피베린의 제조방법 |
| KR100510788B1 (ko) | 2003-07-22 | 2005-08-26 | 동방에프티엘 주식회사 | 프로필벤질릭산 에스터로부터 염산 프로피베린의 제조방법 |
| PT1713473E (pt) * | 2004-02-06 | 2013-05-13 | Meda Pharma Gmbh & Co Kg | Combinação de anticolinérgicos e glucocorticóides para o tratamento a longo prazo de asma e copd |
| EP1921989A2 (en) * | 2005-08-12 | 2008-05-21 | The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services | Neuronal avalanche assay |
| CN1951938A (zh) * | 2005-10-21 | 2007-04-25 | 刘丽娅 | 戊乙奎醚季铵盐及其衍生物 |
| SE0600876L (sv) | 2006-04-20 | 2007-10-21 | Sandvik Intellectual Property | Verktyg och skär för spånavskiljande bearbetning med primära och sekundära ingreppsmedel med rotationssymmetrisk form |
| EP2013172A4 (en) | 2006-04-24 | 2010-08-04 | Astrazeneca Ab | NEW ALKYLESTERS FROM CYCLIC AMINO ALCOHOLS WITH MUSCARIN M3 RECEPTORANTAGONOSTIC ACTIVITY FOR THE TREATMENT OF CHRONIC BRONCHIA SUPPRESSION, ASTHMA OR OVERACTIVE HARNBASE |
| CN101490003A (zh) * | 2006-04-24 | 2009-07-22 | 阿斯利康(瑞典)有限公司 | 具有毒蕈碱m3受体拮抗剂活性、用于治疗入慢性支气管阻塞、哮喘和膀胱过动的新型环状氨基醇的取代烷基酯类化合物 |
| EP2470504B1 (en) * | 2010-03-15 | 2013-10-16 | Ramesha Andagar Ramakrishna | Synthesis of propiverine hydrochloride |
| KR101149821B1 (ko) | 2010-04-05 | 2012-05-24 | 하나제약 주식회사 | 디페닐아세테이트 유도체의 새로운 제조방법 |
| CN102218063B (zh) | 2011-04-12 | 2013-03-13 | 贵州神奇制药有限公司 | 盐酸丙哌维林药物的制备方法和产品及其检测方法 |
| WO2014039627A1 (en) * | 2012-09-05 | 2014-03-13 | Chase Pharmaceuticals Corporation | Anticholinergic neuroprotective composition and methods |
-
2013
- 2013-07-30 AU AU2013300009A patent/AU2013300009B2/en not_active Ceased
- 2013-07-30 CA CA2881182A patent/CA2881182C/en active Active
- 2013-07-30 EP EP13827594.6A patent/EP2882711B1/en active Active
- 2013-07-30 CN CN201380042085.3A patent/CN104603108A/zh active Pending
- 2013-07-30 IN IN1018DEN2015 patent/IN2015DN01018A/en unknown
- 2013-07-30 BR BR112015002832-2A patent/BR112015002832B1/pt not_active IP Right Cessation
- 2013-07-30 KR KR1020207005139A patent/KR102240999B1/ko not_active Expired - Fee Related
- 2013-07-30 KR KR20157006047A patent/KR20150040355A/ko not_active Ceased
- 2013-07-30 JP JP2015526567A patent/JP6345665B2/ja not_active Expired - Fee Related
- 2013-07-30 CN CN201810664740.3A patent/CN108658842A/zh active Pending
- 2013-07-30 HK HK15112219.3A patent/HK1211572A1/xx unknown
- 2013-07-30 WO PCT/US2013/052626 patent/WO2014025569A1/en not_active Ceased
- 2013-07-30 US US14/419,381 patent/US9896416B2/en active Active
- 2013-07-30 MX MX2015001769A patent/MX356386B/es active IP Right Grant
- 2013-07-30 EA EA201500209A patent/EA029678B9/ru unknown
-
2015
- 2015-01-29 IL IL236996A patent/IL236996A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2013300009B2 (en) | 2017-06-15 |
| EP2882711A1 (en) | 2015-06-17 |
| CN104603108A (zh) | 2015-05-06 |
| BR112015002832A2 (enExample) | 2017-07-04 |
| WO2014025569A1 (en) | 2014-02-13 |
| CN108658842A (zh) | 2018-10-16 |
| CA2881182C (en) | 2021-01-26 |
| US20150203452A1 (en) | 2015-07-23 |
| AU2013300009A1 (en) | 2015-02-26 |
| US9896416B2 (en) | 2018-02-20 |
| KR20200022522A (ko) | 2020-03-03 |
| JP6345665B2 (ja) | 2018-06-20 |
| KR20150040355A (ko) | 2015-04-14 |
| EA029678B1 (ru) | 2018-04-30 |
| EA201500209A1 (ru) | 2015-05-29 |
| EP2882711B1 (en) | 2017-10-25 |
| MX356386B (es) | 2018-05-28 |
| EP2882711A4 (en) | 2016-02-10 |
| JP2015524469A (ja) | 2015-08-24 |
| EA029678B9 (ru) | 2018-07-31 |
| CA2881182A1 (en) | 2014-02-13 |
| BR112015002832B1 (pt) | 2022-08-16 |
| IN2015DN01018A (enExample) | 2015-06-26 |
| KR102240999B1 (ko) | 2021-04-15 |
| HK1211572A1 (en) | 2016-05-27 |
| MX2015001769A (es) | 2015-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL290378A (en) | Pharmaceutical compositions containing dimethyl fumarate | |
| ZA201503594B (en) | Pharmaceutical compositions | |
| ZA201501930B (en) | Pharmaceutical composition | |
| EP2832730A4 (en) | MIRABEGRAPHIC PHARMACEUTICAL COMPOSITION | |
| SG11201403875VA (en) | Oral pharmaceutical composition | |
| ZA201409020B (en) | Pharmaceutical formulation | |
| GB201205164D0 (en) | Pharmaceutical compounds | |
| ZA201405925B (en) | Pharmaceutical formulation having improved stability | |
| IL236996A0 (en) | Pharmaceutical preparations containing quaternized piperidinium salts | |
| IL239512A0 (en) | Pharmaceutical compounds | |
| ZA201502987B (en) | Pharmaceutical composition | |
| IL233327A (en) | A derivative of proxatin | |
| GB201202027D0 (en) | Pharmaceutical compounds | |
| GB201211153D0 (en) | Pharmaceutical compositions | |
| SG11201406097SA (en) | Capsule formulation | |
| PL2760822T3 (pl) | Sole desfezoterodyny | |
| IL238075A0 (en) | pharmaceutical preparations | |
| GB201219234D0 (en) | Pharmaceutical compositions | |
| GB201213303D0 (en) | Pharmaceutical compositions | |
| GB201204810D0 (en) | Pharmaceutical compositions | |
| ZA201400751B (en) | Pharmaceutical composition | |
| GB201219236D0 (en) | Pharmaceutical compounds | |
| GB201214121D0 (en) | Pharmaceutical compounds | |
| GB201213519D0 (en) | Pharmaceutical compounds | |
| GB201203253D0 (en) | Pharmaceutical compounds |